Multivalued Logic Assay of the Disease Marker of α-Ketoglutaric Acid by a Luminescent MOF-Based Biosensor

2020 ◽  
Vol 3 (6) ◽  
pp. 3792-3799
Author(s):  
Xu Dai ◽  
Ji-Na Hao ◽  
Jinlou Gu ◽  
Yongsheng Li
Keyword(s):  
Multivalued Logic ◽  
Disease Marker

A likelihood ratio test for detecting patterns of disease-marker association

1997 ◽  
Vol 61 (4) ◽  
pp. 335-350 ◽  
Author(s):  
A. P. MORRIS ◽  
J. C. WHITTAKER ◽  
R. N. CURNOW
Keyword(s):  
Likelihood Ratio ◽  
Likelihood Ratio Test ◽  
Ratio Test ◽  
Disease Marker

On the action of the implicative closure operator on the set of partial functions of the multivalued logic

2021 ◽  
Vol 31 (3) ◽  
pp. 155-164
Author(s):  
Sergey S. Marchenkov
Keyword(s):  
Closure Operator ◽  
Multivalued Logic ◽  
Partial Functions ◽  
Logical Implication

Abstract On the set P k ∗ $\begin{array}{} \displaystyle P_k^* \end{array}$ of partial functions of the k-valued logic, we consider the implicative closure operator, which is the extension of the parametric closure operator via the logical implication. It is proved that, for any k ⩾ 2, the number of implicative closed classes in P k ∗ $\begin{array}{} \displaystyle P_k^* \end{array}$ is finite. For any k ⩾ 2, in P k ∗ $\begin{array}{} \displaystyle P_k^* \end{array}$ two series of implicative closed classes are defined. We show that these two series exhaust all implicative precomplete classes. We also identify all 8 atoms of the lattice of implicative closed classes in P 3 ∗ $\begin{array}{} \displaystyle P_3^* \end{array}$ .

scholarly journals Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Alan Bénard ◽  
Anne Jacobsen ◽  
Maximilian Brunner ◽  
Christian Krautz ◽  
Bettina Klösch ◽  
...  
Keyword(s):  
Viral Load ◽  
Viral Infections ◽  
Predictive Marker ◽  
Pulmonary Diseases ◽  
Potential Therapeutic Target ◽  
Multicentric Study ◽  
Independent Prognostic Marker ◽  
Disease Marker ◽  
Infection Treatment ◽  
Innate Antiviral Immunity

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123+ epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.

scholarly journals Recent Advances on Multivalued Logic Gates: A Materials Perspective

2021 ◽  
Vol 8 (8) ◽  
pp. 2004216
Author(s):  
Sae Byeok Jo ◽  
Joohoon Kang ◽  
Jeong Ho Cho
Keyword(s):  
Logic Gates ◽  
Multivalued Logic ◽  
Recent Advances

scholarly journals The Stromelysin-1 5A/6A Promoter Polymorphism Is a Disease Marker for the Extent of Coronary Heart Disease

2002 ◽  
Vol 18 (3) ◽  
pp. 121-128 ◽  
Author(s):  
Adelheid Schwarz ◽  
Werner Haberbosch ◽  
Harald Tillmanns ◽  
Andreas Gardemann
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Total Sample ◽  
Promoter Polymorphism ◽  
Mean Values ◽  
Glucose Levels ◽  
Disease Marker ◽  
Triple Vessel Disease ◽  
Artery Disease ◽  
Glucose Plasma

Background.Matrix metalloproteinases, such as stromelysin-1, are implicated in the pathogenesis of coronary artery disease (CAD) and acute myocardial infarction (MI). A 5A/6A promoter polymorphism can regulate the transcription of the stromelysin-1 gene in an allele-specific manner. Evidence has been presented that the 6A allele is associated with the progression of coronary heart disease (CHD). In contrast, the 5A allele may be linked to the risk of MI.Results.To analyse the relation of the 5A/6A polymorphism with the risk and severity of CHD and the risk of MI, a case-control study of 515 healthy controls and 1848 participants who underwent coronary angiography for diagnostic purposes was conducted. In the total sample, the mean CHD scores—according to Gensini—were different between 5A/6A genotypes: 5A5A homozygotes had the lowest, 6A6A genotypes the highest and 5A6A heterozygotes intermediate scores. These differences were even more pronounced when the participants were restricted to individuals with a high coronary risk profile (high apoB levels, high Lp(a) levels, high glucose levels, combinations of either high apoB and Lp(a) levels or high apoB, Lp(a) and glucose plasma levels). Mean values were used as cut points for high-risk populations, respectively. In contrast, the 5A allele was not associated with the risk of CHD or MI. Even when angiographically controlled individuals without MI were compared with MI patients in subpopulations of participants with no, single, double and triple vessel disease, the frequencies of the 5A/6A and/or the 5A5A genotypes were not higher in each subgroup, respectively.Conclusions.The present results do not confirm an association of the 5A allele with the risk of MI, observed in another investigation, but strengthen the hypothesis of earlier studies that the 6A allele is a disease marker for progression of coronary heart disease. Further investigations should evaluate whether 6A allele carriers and especially 6A homozygotes might benefit from a more aggressive therapy against CHD progression.

Sign in / Sign up

Export Citation Format

Share Document